Sign inCreate account

Report workspace tools

NCT01266213UNKNOWNanonymous

Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman

Sponsor

Source record

Samsung Medical Center

Phase

Source record

Phase II

Modality

AI-normalized

small molecule

Target

AI-normalized

Estrogen Receptor Positive Tumor

Indication / condition

AI-normalized

Metastatic Breast Cancer

Intervention

Source record

Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin

Source & freshness

Source record

NCT ID

NCT01266213

Original source

ClinicalTrials.gov

Source last updated

May 01, 2017

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01266213

Title

Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman

Sponsor

Samsung Medical Center

Status

UNKNOWN

Phase

Phase II

Condition raw

Metastatic Breast Cancer

Condition normalized

Metastatic Breast Cancer

Modality raw

Metastatic Breast Cancer

Modality normalized

small molecule

Target raw

Estrogen Receptor Positive Tumor

Target normalized

Estrogen Receptor Positive Tumor

Interventions

Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin

Public preview

Source record

This clinical trial evaluates the efficacy of high-dose Fulvestrant combined with Goserelin compared to Anastrozole with Goserelin and Goserelin alone in premenopausal women with recurrent or metastatic hormone receptor-positive breast cancer who have previously been treated with Tamoxifen. The study aims to determine the best treatment approach for this patient population.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01266213

Status

UNKNOWN

Phase

Phase II

Sponsor

Samsung Medical Center

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the efficacy of high-dose Fulvestrant combined with Goserelin compared to Anastrozole with Goserelin and Goserelin alone in premenopausal women with recurrent or metastatic hormone receptor-positive breast cancer who have previously been treated with Tamoxifen. The study aims to determine the best treatment approach for this patient population.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 01, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01266213

Indication

Metastatic Breast Cancer

Modality

small molecule

Target

Estrogen Receptor Positive Tumor

Intervention

Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.